Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond

Area of Science:

• Cardiovascular Biology
• Immunology
• Inflammation Research

Background:

• Inflammatory pathways are central to the development of atherosclerosis.
• Conventional risk factors contribute to cardiovascular disease through inflammation.
• Interleukin-1 beta (IL-1β) has emerged as a significant therapeutic target.

Purpose of the Study:

• To review the evidence supporting IL-1β's role in atherogenesis.
• To highlight the potential of anti-inflammatory therapies targeting IL-1β.
• To illustrate the translation of basic vascular biology into clinical practice.

Main Methods:

• Review of experimental and clinical evidence on IL-1β in cardiovascular disease.
• Analysis of IL-1β production by vascular cells and leukocytes.
• Examination of inflammasome activation in atherosclerotic plaques.

Main Results:

• IL-1β is produced by intrinsic vascular wall cells and lesional leukocytes.
• The inflammasome facilitates the generation of active IL-1β within plaques.
• Clinical interventions targeting IL-1 action demonstrate improved cardiovascular outcomes.

Conclusions:

• IL-1β is a critical local and systemic mediator in atherosclerosis.
• Anti-inflammatory therapies targeting IL-1β represent a new era in cardiovascular treatment.
• Biomarker-directed, personalized therapy offers improved outcomes for cardiovascular patients.